Home Tags NBE-002

Tag: NBE-002

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....

Boehringer Ingelheim Venture Fund and PPF Group Close a US $...

Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development

Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development of NBE-002, the company's first...